

Table S1 Abbreviation list of 33 cancers from the TCGA

Abbreviation	Full term
ACC	Adrenocortical carcinoma
BLCA	Bladder urothelial carcinoma
BRCA	Breast invasive carcinoma
CESC	Cervical squamous cell carcinoma and endocervical adenocarcinoma
CHOL	Cholangiocarcinoma
COAD	Colon adenocarcinoma
COADREAD	Colon adenocarcinoma/rectum adenocarcinoma esophageal carcinoma
DLBC	Lymphoid neoplasm diffuse large B-cell lymphoma
ESCA	Esophageal carcinoma
FPPP	FFPE pilot phase II
GBM	Glioblastoma multiforme
GBMLGG	Glioma
HNSC	Head and neck squamous cell carcinoma
KICH	Kidney chromophobe
KIPAN	Pan-kidney cohort (KICH + KIRC + KIRP)
KIRC	Kidney renal clear cell carcinoma
KIRP	Kidney renal papillary cell carcinoma
LAML	Acute myeloid leukemia
LGG	Brain lower grade glioma
LIHC	Liver hepatocellular carcinoma
LUAD	Lung adenocarcinoma
LUSC	Lung squamous cell carcinoma
MESO	Mesothelioma
OV	Ovarian serous cystadenocarcinoma
PAAD	Pancreatic adenocarcinoma
PCPG	Pheochromocytoma and Paraganglioma
PRAD	Prostate adenocarcinoma
READ	Rectum adenocarcinoma
SARC	Sarcoma
SKCM	Skin cutaneous melanoma
STAD	Stomach adenocarcinoma
STES	Stomach and esophageal carcinoma
TGCT	Testicular germ cell tumors
THCA	Thyroid carcinoma
THYM	Thymoma
UCEC	Uterine corpus endometrial carcinoma
UCS	Uterine carcinosarcoma
UVM	Uveal melanoma

Table S2 Basic information of GEO datasets included in this study

Cancer type	Datasets	Sample type	
		Normal (n)	Tumor (n)
BLCA	GSE13507	68	188
BRCA	GSE70947	148	148
CESC	GSE63514	100	28
CHOL	GSE26566	36	100
COAD	GSE166427	148	98
ESCA	GSE53625	179	179
GBM	GSE108474	28	295
HNSC	GSE13601	26	31
KIRP	GSE26574	10	34
LIHC	GSE89377	67	41
LUAD	GSE75037	83	83
LUSC	GSE18842	45	46

GEO, Gene Expression Omnibus.

Table S3 RPN1 expression for response and non-response based on pre-treatment samples in each dataset

Study	Cancers	Anti-target	Response mean	Non-response mean	Log ₂ FC	P value	FDR
IMvigor210	Urothelial cancer	Anti-PD-L1	15,324.16	12,252.90	0.24	0.001	0.011
SRP217040	Non-small cell lung cancer	Anti-PD-L1	11,460.00	8,264.00	0.507	0.024	0.213
SRP230414	Melanoma	Anti-PD-1	17,035.00	20,126.00	-0.455	0.023	0.345
SRP070710	Melanoma	Anti-PD-1	16,011.00	17,133.00	-0.369	0.068	0.468
SRP011540	Melanoma	Anti-PD-1	5,509.50	5,521.00	0.085	0.329	0.63
SRP150548	Melanoma	Anti-PD-1	6,959.00	6,152.00	0.862	0.179	0.634
SRP155030	Glioblastoma	Anti-PD-1	4,549.50	4,487.50	0.291	0.18	0.724
ERP105482	Melanoma	Anti-PD-1	6,912.00	6,649.50	0.151	0.371	0.743
SRP183455	Non-small cell lung cancer	Anti-PD-1	6,056.00	6,587.00	0.317	0.478	0.774
ERP105482	Melanoma	Anti-PD-1 + anti-CTLA4	9,098.00	8,832.00	0.135	0.478	0.84
ERP107734	Gastric cancer	Anti-PD-1	10,346.00	8,400.00	0.052	0.703	0.875
GSE111636	Urothelial cancer	Anti-PD-1	3.97	3.67	0.306	0.207	0.91
SRP094781	Melanoma	Anti-PD-1	8,755.00	10,184.00	-0.059	0.683	0.936
PMID:33806963	Renal cell carcinoma	Anti-PD-1	12.6	12.27	0.332	0.214	0.939
GSE176307	Urothelial cancer	Anti-PD-1	12.72	12.65	0.069	0.608	0.954
SRP128156	RCC	Anti-PD-1/anti-PD-1 + anti-CTLA4	8,271.50	7,926.00	-0.168	0.494	0.959
PMID:32472114	Renal cell carcinoma	Anti-PD-1	34.73	34.78	-0.05	0.616	0.981
TCGA	Melanoma	Anti-CTLA4	12.56	12.92	-0.357	0.426	0.995
SRP011540	Melanoma	Anti-CTLA4	8,884.00	8,418.00	-0.027	0.905	0.996
GSE122220	Melanoma	Anti-PD-1	11.91	11.84	0.074	0.819	0.996
SRP250849	Melanoma	Anti-PD-1	3,342.67	3,798.50	-0.004	0.993	0.999
GSE99070	Malignant pleural mesothelioma	Anti-PD-1	9.97	9.69	0.283	0.33	1
GSE67501	Renal cell carcinoma	Anti-PD-1	11.24	11.35	-0.113	0.529	1
SRP128156	Renal cell carcinoma	Anti-PD-1 + anti-CTLA4	10,661.00	3,044.00	0.975	0.246	1
SRP128156	Renal cell carcinoma	Anti-PD-1	8,211.00	8,138.00	-0.185	0.592	1

FC, fold change; FDR, false discovery rate; TCGA, The Cancer Genome Atlas.




Figure S1 Analysis the expression of A549 and MDA-MB-231 with knockout RPN-1. Western blot analysis was conducted to assess the expression levels of RPN1 in the A549 and MDA-MB-231 cell lines following gene knockout. The NC group received no gene editing, while knockout groups KO1 and KO2 represent two distinct gene ablation variants. GAPDH was employed as a loading control to ensure equal protein quantification across samples. NC, negative control; KO, knockout.

